FierceBiotechOriginal article
{"a":[{"_":"Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail","$":{"href":"/biotech/evommune-gives-hope-mrgprx2-antagonist-treat-itch-after-second-phase-2-fail","hreflang":"en"}}]}
Phase 2negativeMRGPRX2 antagonistNegative
AI Analysis
Summary
Evommune's MRGPRX2 antagonist failed a phase 2 trial for itch-related conditions, leading the company to discontinue development of the therapy. This represents the second phase 2 failure for the program.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Phase 2 trial failed; program discontinued for itch-related indications
Importance:5/10
Sentiment:
-0.90
Phase 2 failureprogram discontinuationMRGPRX2itch treatment
Read the original article
Published by FierceBiotech on September 9, 2026 4:06 AM